Once daily aerosolised tobramycin in adult patients with cystic fibrosis in the management of Pseudomonas aeruginosa chronic infection

It is estimated that about 60–70% of Cystic Fibrosis patients develop Pseudomonas aeruginosa chronic infection, with progressive loss of lung function, as well as increased antibiotic resistance and mortality. The current strategy is to maintain lung function by chronic suppressive antipseudomonas a...

Descripción completa

Detalles Bibliográficos
Autores principales: Mantero, Marco, Gramegna, Andrea, Pizzamiglio, Giovanna, D’Adda, Alice, Tarsia, Paolo, Blasi, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5294814/
https://www.ncbi.nlm.nih.gov/pubmed/28184305
http://dx.doi.org/10.1186/s40248-016-0083-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5294814/
https://www.ncbi.nlm.nih.gov/pubmed/28184305
http://dx.doi.org/10.1186/s40248-016-0083-y

Ejemplares similares